1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > China Insulin Industry Report, 2012-2015

China Insulin Industry Report, 2012-2015

  • January 2013
  • -
  • Research In China
  • -
  • 70 pages

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.

Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.

Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China’s insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.

America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market. In May, 2012, Eli Lilly and Company China R&D center was formally opened in Shanghai, dedicated to the R&D of diabetes medicines; in June, the Suzhou-based insulin extension project with the investment exceeding USD40 million was also put into service.?

Jilin-based Tonghua Dongbao Pharmaceutical is China’s largest recombinant human insulin producer, with the insulin API capacity of 3,000 kg and the insulin preparation capacity of 70 million bottles or 6% market share in China’s recombinant human insulin market. In 2012, the company’s recombinant human insulin injection phase - project with the annual capacity of insulin preparation targeting 126 million pcs started construction, and it is expected to be put into production in Q4 2013.?

As the world’s fourth and China’s first insulin analog producer, Gan & Lee Pharmaceuticals realized the market share of 6% in China’s insulin analog market in 2011. In April 2012, the insulin phase - project of the company held the groundbreaking ceremony. Once the project is put into production as scheduled, the company is expected to increase its capacity of insulin API by 750kg/a and of insulin preparation by 38.5 mln pcs/a.

Enterprises including Hisun Pharmaceutical, United Laboratories and Bayer, with positive outlook of demand for insulin in the Chinese market, are beefing up gaining ground in China through developing new products, building new production bases and agent marketing.


The report highlights the followings:

Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc.
China insulin industry: development, supply & demand, import & export, competition pattern, policy environment, development trend, etc.
Operation, insulin business analysis and development outlook of seven insulin producers worldwide.

Table Of Contents

China Insulin Industry Report, 2012-2015
1. Insulin Overview
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Global Insulin Market Development
2.1 Status Quo
2.2 Supply and Demand
2.3 Product RandD
2.4 Competition Pattern
2.5 Development Trend

3. China Insulin Market Development
3.1 Status Quo
3.2 Supply and Demand
3.3 Export
3.4 Import
3.5 Competition Pattern
3.6 Price
3.7 Policy
3.8 Development Trend

4. Key Insulin Manufacturers
4.1 Novo Nordisk
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 RandD and Investment
4.1.6 Insulin Business
4.1.7 Business in China
4.1.8 Development Prospect
4.2 Eli Lilly and Company
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 RandD and Investment
4.2.6 Insulin Business
4.2.7 Business in China
4.2.8 Development Prospect
4.3 Sanofi Group
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 RandD and Investment
4.3.6 Insulin Business
4.3.7 Business in China
4.3.8 Development Prospect
4.4 Tonghua Dongbao Pharmaceutical Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Customers
4.4.6 R and D and Investment
4.4.7 Insulin Business
4.4.8 Development Prospect
4.5 Wanbang Biopharmaceuticals
4.5.1 Profile
4.5.2 Operation
4.6 Gan and Lee Pharmaceuticals
4.6.1 Profile
4.6.2 Operation
4.7 Nanjing Xinbai Pharmaceutical Co. Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Insulin Business





Selected Charts

Diabetes Types
Classification of Insulin by Technological Level/Time
Recombiant Human Insulin Production Carrier and Featuers
Insulin Industy Chain
World's Population of Diabetics, 2005-2012
Population of Diabetics in the World's Top 10 Countries by Diabetes Developers, 2011
Market Size of the World's Top 10 Diabetes Medicines, 2011
Market Scale of Diabetes Medicines Worldwide and YoY Growth Rate, 2004-2011
Global Diabetics Market Occupancy by Medicine, 2006-2011
Global Insulin Market Scale and YoY Growth Rate, 2005-2011
Theoretic Demand for Insulin API Worldwide, 2011
Average Per Capita Insulin Consumption Worldwide by Nation, 2000-2010
RandD Advance of Some Insulin Products Worldwide as of late Jun. 2012
Global Insulin Pump Market Scale, 2009/2016
Global Insulin Market Share by Enterprise, 2011
Global Insulin Production Line and RandD Input Share by Enterprise, 2011
Population of Diabetics in China, 2007-2011
Market Scale of Diabetes Medicines in China and YoY Growth Rate, 2004-2011
Insulin Medicine Market Share in China, 2006-2011
Market Share of Diabetes Treatment Hospitals in China by Medicine, 2005-2010
Export Value and Export Price of Insulin and Insulin Salts of China, 2008-2012
Export Destinations of Insulin and Insulin Salts in China and Proportions, 2011
Export Value of Insulin-Containing Medicines with Unmeasued Dose in China,2010-2012
Export Value of Insulin-Containing Medicines with Measued Dose in China by Nation and Proportions, 2011
Export Value of Insulin-Containing Medicines with Measued Dose in China and YoY Growth Rate, 2008-2012
Export Value of Insulin-Containing Medicines with Measued Dose in China by Nation, 2011
Import Value of Insulin and Insulin Salts and YoY Growth Rate in China, 2008-2011
Import Value of Insulin and Insulin Salts in China by Country, 2011
Import Value of Insulin-Containing Medicines with Measued Dose and YoY Growth Rate in China, 2008-2012
Import Value of Insulin-Containing Medicines with Measued Dose in China by Country, 2011
Import Value of Insulin Medicines in Representative Hospticals in 22 Cities across China by Variety, 2008-2011
Competitive Enterprises and Market Share in China Insulin Market, 2011
Competition Pattern of China Recombinant Human Insulin Market, 2011
Competition Pattern of China Insulin Analog Market by Enterprise, 2011
Ceiling Retail Price of Some Insulin Products in China, 2011
Insulin Medicines Included in National Health Insurance Directory, 2012
Key Strategy of Novo Nordisk
Revenue and YoY Growth Rate of Novo Nordisk, 2007-2012
Net Income and YoY Growth Rate of Novo Nordisk, 2007-2012
Revenue of Novo Nordisk by Product, 2007-2012
Revenue of Novo Nordisk by Region, 2007-2012
Gross Margin of Novo Nordisk, 2007-2012
RandD Expenditure of Novo Nordisk by Field, 2007-2011
Insulin Market Share of Novo Nordisk by Country, 2011-2012
Revenue from Insulin Business of Novo Nordisk by Mark, 2009-2012
Distribution of Subsidaries under Novo Nordisk in China
Revenue and YoY Growth Rate of Novo Nordisk in China, 2007-2012
Revenue, Net Income and YoY Growth Rate of Novo Nordisk, 2010-2015
Revenue and YoY Growth Rate of Eli Lilly and Company, 2007-2012
Net Income and YoY Growth Rate of Eli Lilly and Company, 2007-2012
Revenue of Eli Lilly and Company by Field, 2009-2011
Revenue of Eli Lilly and Company by Region, 2009-2011
Consolidated Gross Margin of Eli Lilly and Company, 2008-2012
RandD Expenditure and YoY Growth Rate of Eli Lilly and Company, 2007-2012
Cooperative Enterperises with Eli Lilly and Company by Product, 2011
Revenue and YoY Growth Rate from Insulin Business of Eli Lilly and Company by Product, 2008-2012
Revenue from Insulin Business of Eli Lilly and Company by Region, 2008-2012
Revenue, Net Income and YoY Growth Rate of Eli Lilly and Company, 2010-2015
Revenue and YoY Growth Rate of Sanofi Group, 2007-2012
Net Income and YoY Growth Rate of Sanofi Group, 2007-2012
Revenue of Sanofi Group by Business, 2008-2012
Revenue of Sanofi Group by Region, 2008-2012
Consolidated Gross Margin of Sanofi Group, 2007-2012
RandD Expenditure of Sanofi Group by Business, 2008-2012
Revenue and YoY Growth Rate from Insulin Business of Sanofi Group by Product, 2008-2012
Distribution of Subsidaries under Sanofi Group, 2011
Revenue and YoY Growth Rate of Sanofi Group in China, 2009-2012
Revenue, Net Income and YoY Growth Rate of Sanofi Group, 2010-2015
Distribution of Subsidaries under Tonghua Dongbao Pharmaceutical, 2011
Revenue and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012
Net Income and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012
Revenue of Tonghua Dongbao Pharmaceutical by Product, 2007-2012
Revenue of Tonghua Dongbao Pharmaceutical by Region, 2007-2012
Gross Margin of Tonghua Dongbao Pharmaceutical by Product, 2007-2012
Tonghua Dongbao Pharmaceutical's Revenue from Top 5 Clients and % of Total Revenue, 2009-2012
Namelist and Revenue Contribution of Tonghua Dongbao Pharmaceutical's Top 5 Clients, 2011-2012
Revenue and YoY Growth Rate from Insulin Business of Tonghua Dongbao Pharmaceutical, 2007-2012
Revenue, Net Income and YoY Growht Rate of Tonghua Dongbao Pharmaceutical, 2010-2015
Holding Subsidiaries of Wanbang Biopharmaceuticals
Total Assets and Net Income of Wanbang Biopharmaceuticals, 2009-2011
Insulin Products of Gan and Lee Pharmaceuticals
Revenue and Net Income of Gan and Lee Pharmaceuticals, 2008-2010
Revenue, Net Income and YoY Growth Rate of Nanjing Xinbai Pharmaceutical, 2007-2011
Revenue from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011
Gross Profit and Gross Margin from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Type 2 Diabetes Mellitus: KOL Insight 2016

Type 2 Diabetes Mellitus: KOL Insight 2016

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists ...

European Market Report for Modern Insulin 2016 - MedCore

European Market Report for Modern Insulin 2016 - MedCore

  • $ 5995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Related Market Segments :

Insulin

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.